{"id":"hs-10241-almonertinib","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4761468","moleculeType":"Small molecule","molecularWeight":"525.66"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HS-10241 selectively inhibits mutant EGFR while sparing wild-type EGFR, addressing resistance mechanisms that emerge during treatment with earlier-generation inhibitors. The combination with almonertinib targets multiple EGFR pathways and resistance mutations, particularly in non-small cell lung cancer with EGFR sensitizing mutations. This dual-targeting approach aims to overcome acquired resistance and improve progression-free survival.","oneSentence":"HS-10241 is a third-generation EGFR tyrosine kinase inhibitor designed to target EGFR mutations including common and uncommon variants, often combined with almonertinib (a third-generation EGFR-TKI) to enhance efficacy against resistant lung cancers.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:45:51.013Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer with EGFR mutations (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT06110663","phase":"PHASE3","title":"A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2023-12-30","conditions":"Non-Small Cell Lung Cancer","enrollment":314},{"nctId":"NCT05430386","phase":"PHASE1","title":"Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2022-01-05","conditions":"Non Small Cell Lung Cancer","enrollment":174}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HS-10241+ Almonertinib","genericName":"HS-10241+ Almonertinib","companyName":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","companyId":"jiangsu-hansoh-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HS-10241 is a third-generation EGFR tyrosine kinase inhibitor designed to target EGFR mutations including common and uncommon variants, often combined with almonertinib (a third-generation EGFR-TKI) to enhance efficacy against resistant lung cancers. Used for Non-small cell lung cancer with EGFR mutations (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}